NeuroQuant®: Contrast agents not required

Factors which degrade the technical quality of MR images or pathologic processes, which significantly affect neuroanatomic structure, may decrease the accuracy of NeuroQuant® output. One of these factors is the use of contrast agents.

Contrast agents are typically used to study vasculature, something that is not needed for volumetric MR imaging. NeuroQuant requires a non-contrasted, 3D T1 sagittal sequence to segment and measure brain structure volumes.

NeuroQuant does not support a contrast enhanced study. The presence of contrast will cause misregistration of cortical and subcortical structures. The segmentation, volumetrics and normative comparisons will be inaccurate when contrast agents are used.

Some examples of NeuroQuant processed with and without contrast agents are shown below.

Cortechs.ai | NeuroQuant<sup>®</sup>: Contrast agents not required

More information about using NeuroQuant can be found here.

More Resources

03/09/2025

Advancing TBI Evaluation with AI-Driven MRI Analysis: A New Era in Brain Health

AI-driven MRI with NeuroQuant® enhances TBI assessment, tracks recovery, and supports better treatment decisions.

03/06/2025

Case Study: Leveraging NeuroQuant® for Accurate Diagnosis of Traumatic Brain Injury

This case highlights the power of advanced neuroimaging tools in delivering precise, evidence-based diagnostics to enhance patient care and clinical decisions.

02/26/2025

Traumatic Brain Injury in Athletes: The Role of the NeuroQuant and Automated Volumetric Tracking

NeuroQuant enables objective brain volume tracking for early TBI detection, recovery monitoring, and safer return-to-play decisions.

02/25/2025

OnQ™ Prostate Solution Enhances Collaboration and Improves MRI for Cancer Detection with RSI Technology

OnQ Prostate enhances MRI tissue characterization, improving sensitivity and specificity in cancer detection, & bridges gaps between radiologists and urologists

02/15/2025

NeuroQuant® Dementia: Advancing Alzheimer’s Disease Care in the Era of DMTs

AI-driven brain volumetric analysis is revolutionizing Alzheimer’s care, providing precise diagnostic support, monitoring, and early detection.

02/09/2025

NeuroQuant® MS:  Advancing Precision in Multiple Sclerosis

Dr. Suzie Bash discusses NeuroQuant MS, noting its ability to segment plaques, analyze volume, and track lesion burden for assessing disease progression
Scroll to Top